TrialAnnals of oncology : official journal of the European Society for Medical Oncology2014

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

B Chauffert et al.PubMed ↗Publisher ↗

No numbers read from the abstract.